DeepIntent today announced a partnership with Lane4.io, the first supply-side platform purpose-built for electronic health record and health media advertising, completing a set of three point-of-care deals the healthcare DSP disclosed this week. The Lane4.io agreement, announced May 28, 2026, follows integrations with OptimizeRx and epocrates that were announced in the days prior. Taken together, the moves mark a significant escalation in the company's effort to make point-of-care inventory accessible within standard programmatic workflows.

The partnerships are not incremental. They attempt to resolve a structural limitation that has persisted in healthcare marketing for years: EHR and in-workflow clinical inventory has remained largely siloed, available only through proprietary managed services, and difficult to combine with the kind of omnichannel programmatic campaigns that pharmaceutical brands run across connected TV, display, and audio.

A market that crossed $1 billion

Point-of-care media spend surpassed $1 billion in 2024, according to DeepIntent. That milestone has practical significance for the programmatic industry: it signals that the channel has reached a scale at which infrastructure investment - SSPs, DSP integrations, standardized identity frameworks - starts to make economic sense. Until recently, the fragmented nature of the supply side made it easier for pharma brands to buy POC inventory through dedicated point-of-care vendors rather than route it through the same DSP infrastructure they use for everything else.

That is precisely the gap Lane4.io was built to close. According to DeepIntent, Lane4.io is the first and only SSP built specifically for EHR and health media advertising - a distinction that sets it apart from clinical workflow tools that have been retrofitted for marketing use after the fact. The difference matters technically. Retrofitted tools must bridge the gap between clinical data flows and ad serving infrastructure; Lane4.io's architecture was designed from day one to make EHR inventory activatable programmatically.

What the Lane4.io deal delivers

The technical scope of the partnership is detailed in specifics. According to DeepIntent, clients gain reach across 6 EHR systems and 158,000 unique doctors through the integration. The deal introduces NPI-level trigger-based messaging to the DeepIntent platform - a capability not previously available there. NPI, or National Provider Identifier, is the standardized identification number assigned to US healthcare providers; NPI-level targeting allows a campaign to reach a specific, named clinician at the moment a clinical event - such as writing a prescription for a particular drug class - occurs in the EHR.

That trigger-based mechanism is technically distinct from cookie-based or device-based targeting. Rather than matching an audience segment against an ad opportunity, it fires a message at a clinician in response to a discrete clinical action. The infrastructure required to do this at scale across multiple EHR systems is considerably more complex than standard programmatic buying.

Lane4.io's proprietary clinical event messaging infrastructure also contributes data insights and retail activation capabilities that feed into DeepIntent's measurement stack. According to DeepIntent, POC signals from the integration will enrich measurement and optimization across omnichannel plans - meaning that clinical engagement data gathered at the point of care can inform bidding and audience strategies in other channels such as CTV or streaming audio.

"We're excited to partner with DeepIntent, a company that has set the standard for programmatic healthcare advertising," said Chad Gottfrid, CEO of Lane4.io. "Lane4.io was built from the ground up to make EHR inventory work for marketers, not just for clinical workflows. Together, we're giving pharma brands a clean, scalable way to reach providers at the most important moment in the patient journey."

The capability will be available to DeepIntent clients beginning mid-June 2026.

The OptimizeRx and epocrates integrations

The Lane4.io deal is the third announced within a short window. Earlier this week, DeepIntent disclosed that it had become the first healthcare DSP to integrate OptimizeRx's authenticated EHR network. OptimizeRx, a Nasdaq-listed healthcare technology company (ticker: OPRX), operates a platform that reaches healthcare professionals within clinical workflow environments across a network of EHR and e-prescribing partners. Its authenticated network means that provider identities are verified against NPI data - a meaningful distinction for pharmaceutical advertisers who need to demonstrate compliant targeting of licensed clinicians.

Separately, DeepIntent announced that epocrates' in-workflow clinician inventory is now programmatically available through the platform. Epocrates is a widely used clinical reference tool that healthcare professionals - particularly physicians - access during patient consultations to look up drug interactions, dosing information, and formulary data. That in-workflow context, occurring at the moment a treatment decision is being made, has long been considered among the most valuable placements in healthcare marketing. Making it accessible programmatically, rather than only through a dedicated epocrates buy, changes the economics of accessing that inventory.

The identity and measurement layer

The broader significance of these partnerships is not just access to new supply. It is the combination of that supply with DeepIntent's existing identity infrastructure. According to DeepIntent, the company uniquely unites media, identity, and real-world clinical data to power privacy-safe omnichannel marketing. The Cortex DSP sits on top of that data stack, which covers more than 3.7 million healthcare providers and over 240 million patient lives, as PPC Land reported when DeepIntent launched its Helix healthcare marketing cloud in March 2026.

Deterministic identity is central to how point-of-care targeting works in a compliant environment. Unlike probabilistic audience matching, deterministic identity ties an ad impression to a verified individual - in this case, a licensed healthcare professional whose NPI number is known. When that identity layer is combined with clinical event data from an EHR, the result is a targeting signal that is both precise and contextually relevant in a way that is difficult to replicate outside the clinical environment.

DeepIntent CMO Ian Colley framed the broader significance: "Real-time clinical intent layered with deterministic identity and executed programmatically has been something of a holy grail for healthcare media planners. The infrastructure is now in place to deliver it."

Lisa Kopp Johnson, CRO of DeepIntent, described the commercial framing: "The next era of healthcare marketing is personal, real-time, and increasingly shaped by the moments where care decisions are made. This partnership gives our clients extended reach and scale to activate true omnichannel strategies by connecting point-of-care engagement with measurable outcomes. Alongside companies like Lane4.io, DeepIntent is building the industry's richest marketplace of inventory that's most relevant to the modern healthcare marketer, including point-of-care media."

The competitive landscape

DeepIntent is not operating in isolation. The broader market for programmatic EHR access has attracted multiple players. PulsePoint, a technology company owned by WebMD Health Corp., announced in May 2025 that it had multiplied its point-of-care HCP reach by 10x through new EHR partnerships, giving it access to over 700,000 prescribers across ambulatory and health system settings. In January 2026, PulsePoint announced an exclusive EHR programmatic partnership with Flora Health, making it the only DSP able to access Flora Health's connected health system network at the time.

That competitive context matters. DeepIntent's three simultaneous announcements appear designed to signal that its POC inventory marketplace is expanding at pace - adding OptimizeRx's authenticated network, epocrates' in-workflow inventory, and Lane4.io's purpose-built SSP infrastructure within days of each other.

The regulatory environment also shapes how these partnerships work. Healthcare advertising in programmatic channels operates under constraints that do not apply to consumer categories. Google has required pharmaceutical advertisers using personalized targeting tools to obtain certification when promoting content containing restricted drug terms, and changes to prescription drug advertising policies on Google's Authorized Buyers platform reflect ongoing calibration of how the broader programmatic ecosystem handles pharmaceutical content. For EHR-specific inventory, HIPAA-compliance requirements add another layer of technical and legal complexity.

Why this matters for healthcare marketers

The practical impact for a pharmaceutical media buyer is the possibility of a single campaign that spans EHR workflow placements - through Lane4.io's 6 EHR systems, OptimizeRx's authenticated network, and epocrates' in-consultation inventory - alongside CTV, display, and audio buys, all measured through a common identity and outcomes framework. DeepIntent's earlier expansion into FAST streaming TV and its launch of the HealthFirst Audio Package covering iHeartMedia and SiriusXM provided the non-POC components of that omnichannel picture. The three this-week announcements are intended to fill in the clinical workflow piece.

The measurement implications extend beyond campaign reporting. POC signals - evidence that a clinician was exposed to a message at a moment of prescribing - can, according to DeepIntent, feed back into optimization of display, CTV, or audio placements targeting the same provider. That feedback loop between clinical context and broader media planning has not previously been operable at scale within a single DSP.

Script lift - a metric that measures whether exposed physicians subsequently prescribed the advertised drug at higher rates than unexposed physicians - is the key outcome measure in pharmaceutical advertising. Connecting that clinical signal to programmatic infrastructure requires exactly the kind of NPI-level deterministic matching that the Lane4.io integration introduces.

The SSP layer and why it is structurally different

One dimension of the Lane4.io partnership that deserves attention is what it means for how point-of-care supply reaches a DSP. Most EHR advertising has historically been sold directly - a pharma brand or its agency negotiates a contract with an EHR vendor, buys a defined number of impressions against a defined physician audience, and receives a post-campaign report. The absence of a common SSP layer meant there was no real-time auction, no shared identity framework across publishers, and no standard format for passing audience data back into measurement systems.

Lane4.io's role is to introduce that SSP infrastructure specifically for EHR environments. Its proprietary clinical event messaging infrastructure links EHR inventory to data insights and retail activation in a single programmatic environment. The "retail activation" component is notable: it suggests the capability to connect a clinician's in-EHR exposure to downstream pharmacy data, which is where script lift measurement ultimately lives.

For buyers accustomed to cookie-based programmatic workflows, this represents a different technical model. There are no cookies in an EHR. Identity is established through NPI numbers and authenticated login data - deterministic, not probabilistic. The SSP must handle that identity linkage, pass it through a clean room or privacy-safe environment, and make it actionable for a DSP bidder in something close to real time. That is the infrastructure Lane4.io claims to have built.

Availability and timeline

According to DeepIntent, the Lane4.io capabilities will be available to clients from mid-June 2026. The OptimizeRx and epocrates integrations were announced earlier in the week of May 28, 2026, though exact availability dates for those were not specified in the materials released. The Lane4.io press release was issued May 28, 2026, from New York.

Timeline

  • August 21, 2025 - DeepIntent launches HealthFirst FAST Package for healthcare streaming TV advertising across LG Ad Solutions, Pluto TV, and other platforms. PPC Land coverage
  • September 30, 2025 - DeepIntent launches HealthFirst Audio Package, partnering with iHeartMedia and SiriusXM to reach patients and healthcare providers through streaming audio. PPC Land coverage
  • December 20, 2025 - Google gives programmatic Authorized Buyers new flexibility on prescription drug advertising, modifying EHR-adjacent policy context for healthcare DSPs. PPC Land coverage
  • March 19, 2026 - DeepIntent launches Helix, a HIPAA-ready healthcare marketing cloud covering 3.7 million providers and 240 million patient lives, announced at the company's AdLab forum in New York. PPC Land coverage
  • Week of May 25, 2026 - DeepIntent announces integration with OptimizeRx's authenticated EHR network, becoming the first healthcare DSP to do so.
  • Week of May 25, 2026 - DeepIntent announces that epocrates' in-workflow clinician inventory is now programmatically accessible through its platform.
  • May 28, 2026 - DeepIntent announces partnership with Lane4.io, the first SSP purpose-built for EHR and health media advertising, adding reach across 6 EHR systems and 158,000 unique doctors, with NPI-level trigger-based messaging new to the DeepIntent platform. Capability available to clients from mid-June 2026.

Summary

Who: DeepIntent, the healthcare demand-side platform, along with supply partners Lane4.io, OptimizeRx, and epocrates.

What: Three partnerships announced within the same week that together make EHR and in-workflow point-of-care inventory programmatically accessible through DeepIntent's DSP. The Lane4.io deal specifically adds NPI-level trigger-based messaging, reach across 6 EHR systems and 158,000 unique doctors, and POC measurement signals that feed into omnichannel campaign optimization.

When: The Lane4.io partnership was announced May 28, 2026. The OptimizeRx and epocrates integrations were announced earlier the same week. Lane4.io capabilities will be available to DeepIntent clients beginning mid-June 2026.

Where: DeepIntent is headquartered in New York. Lane4.io, the SSP partner, also operates from the US. The programmatic inventory spans 6 EHR systems and is available across DeepIntent's healthcare DSP infrastructure.

Why: Point-of-care media spend surpassed $1 billion in 2024, and the channel has historically been fragmented and difficult to activate programmatically alongside broader omnichannel campaigns. The three partnerships are an attempt to bring clinical workflow inventory into the same programmatic infrastructure - with shared identity, measurement, and optimization - that pharmaceutical brands already use for CTV, display, and audio.

Share this article
The link has been copied!